ABCSG 65 / DEFINITIVE: First patient randomized
09.10.2025The ABCSG is proud to report that the first Austrian patient has been randomized in the ABCSG 65 / DEFINITIVE trial at LKH Hochsteiermark, site Leoben, under the lead of PI Dr. Thamer Sliwa.
Congratulations to Dr. Sliwa and his dedicated team in Leoben on achieving this important milestone.
ABCSG 65 / DEFINITIVE (Diagnostic HER2DX-guided treatment For patIeNts wIth early-stage HER2-posiTIVE breast cancer) is an international, multicenter, prospective, randomized Phase III trial. The aim is to validate the HER2DX® diagnostic test as a basis for personalized treatment decisions in patients with early-stage HER2-positive breast cancer.
The study investigates whether HER2DX-guided treatment planning can improve health-related quality of life (HRQoL) without compromising treatment efficacy compared with conventional standard approaches.
It is globally coordinated by the Spanish study group SOLTI, while the ABCSG is responsible for the Austrian part.
A total of 315 patients, including 70 in Austria, are planned to be enrolled.
Share on